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Abstract
Background: Notch may behave as an oncogene or a tumor suppressor gene in lung cancer cells. Notch receptor
undergoes cleavage by enzymes, including γ-secretase, generating the active Notch intracellular domain (NICD).
The aim of the present study was to investigate the effect of DAPT, a γ-secretase inhibitor, in non-small cell lung
cancer (NSCLC) cells, as well as the impact of epidermal growth factor (EGF) that is over-expressed by NSCLC cells,
on Notch signaling. H23, A549, H661 and HCC827 human NSCLC cell lines were used, expressing various NICD and
EGF receptor (EGFR) protein levels.
Results: DAPT decreased the number of H661 cells in a concentration-dependent manner, while it had a small
effect on H23 and A549 cells and no effect on HCC827 cells that carry mutated EGFR. Notch inhibition did not
affect the stimulatory effect of EGF on cell proliferation, while EGF prevented DAPT-induced NICD decrease in H23
and H661 cells. The type of cell death induced by DAPT seems to depend on the cell type.
Conclusions: Our data indicate that inhibition of Notch cleavage may not affect cell number in the presence of
EGFR mutations and that EGFR may affect Notch signalling suggesting that a dual inhibition of these pathways
might be promising in NSCLC.
Keywords: Notch intracellular domain, Epidermal growth factor receptor, Non-small cell lung cancer cells,
Apoptosis, Autophagy, Cell cycle arrest
Background
Lung cancer is the leading cause of cancer death. Its in-
cidence and mortality is 52.5/100,000 and 48.7/100,000
per year, respectively [1]. Non-small cell lung cancer
(NSCLC) is the most common subtype, accounting for
approximately 90 % of lung cancer cases [1]. Most pa-
tients are presented with advanced stage disease and
since patient outcomes are largely dependent on stage,
5 year survival rate for lung cancer remains low, at about
15 % [2]. Until recently, chemotherapy with cytotoxic
agents was the only available treatment for lung cancer
[1]. Advances in the research field have led to the
elucidation of unique pathogenic mechanisms, critical
pathways and molecules involved in cancer development,
which have resulted in the introduction of targeted therap-
ies as new treatment options in cancer. A typical example
is the epidermal growth factor receptor (EGFR) activity that
has been found to be overexpressed in about 50–80 % of
NSCLC [3]. Anti-angiogenic agent bevacizumab and EGFR
tyrosine kinase inhibitors erlotinib and gefitinib have been
approved for NSCLC treatment [4, 5]. Moreover, continu-
ous ongoing clinical trials investigate the efficacy and safety
of anti-angiogenic and anti-EGFR agents combinations, as
well as other agents such as multi-targeted anti-angiogenic
tyrosine kinase inhibitors and anti-HER2 agents [6–8].
Despite the existence of many therapeutic options, the
prognosis of patients with metastatic disease remains poor,
with a median survival of about 12 months with the newer
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regimens. This shows how important the development of
new strategies remains. Although targeted therapies are a
step forward, it is essential to clarify the biology of lung
cancer cells [9].
Notch is a transmembrane heterodimeric receptor with
four distinct members (Notch1 to Notch4) in humans and
rodents. Notch signaling pathway is initiated upon ligand
binding, where the receptor subjects into two proteolytic
cleavages. The γ-secretase, a complex enzyme, regulates
the second cleavage of Notch, through which the Notch
intracellular domain (NICD) is liberated to the cytoplasm
and then enters the nucleus in order to activate the tran-
scription of Notch targeted genes [10]. Notch is known for
playing a key role in embryogenesis and organogenesis by
regulating cell proliferation and differentiation [11]. In
addition, Notch seems to be involved in carcinogenesis
and a cell-type dependent profile has been observed with
Notch to act as oncogene or tumor suppressor gene
[12–14]. Both behaviors of Notch have been described in
lung cancer. Notch 1 and 2 proteins are frequently
expressed in NSCLC. Notch 1 is rarely expressed in small
cell lung cancer (SCLC), whereas a subset of SCLC exhibit
Notch 2 expression. It is suspected that Notch has a
growth promoting function in NSCLC, whereas in SCLC
it exerts an inhibitory effect [11, 12]. Research also shows
potential cross talk between Notch pathway and others,
such as EGFR and Wnt [15–19]. Taking those findings to-
gether, Notch pathway is currently under investigation,
with various agents being tested as potential new thera-
peutic options for patients with NSCLC [20].
The cross-talk between the Notch and EGFR signaling
has been previously described in genetic model systems,
where these pathways can function in either an antagonistic
or synergistic fashion, depending on tissue and develop-
mental context [21]. However, the mechanism through
which this interplay occurs, remains unknown [19]. In
breast cancer cells, Notch pathway is used by cancer cells
to compensate for EGFR targeted inhibition [22]. The case
of breast cancer along with previous data from lung
cancers cells demonstrating that Notch 1 might have a
role in acquired resistance to gefitinib [23], prompted
us to investigate the inhibition of Notch in NSCLC cell
lines after cell treatment with γ-secretase inhibitor; N-
[N- (3, 5- difluorophenacetyl)- 1- alanyl]- S- phenylglycine
t- butyl ester (DAPT), as well as the impact of epidermal
growth factor (EGF) in Notch signaling. Our data indi-
cated that Notch inhibition was not effective in all NSCLC
cells and this effect was dependent on EGFR protein levels
and mutations.
Methods
Cell culture and reagents
NSCLC cell lines H23, A549, H661 and HCC827 were
purchased from the American Type Culture Collection
(ATCC) and cultured as manufacturer recommends. Ac-
cording to ATCC, H23, A549 and H661 cells express
wild type EGFR, while HCC827 cells express mutated
EGFR bearing E746-A750 deletion (https://www.lgcstan-
dards-atcc.org/) as shown in Additional file 1: Table S1.
Cells were cultured in RPMI 1640 medium with 2 mM L-
glutamine and supplemented with 1 mM sodium pyruvate,
4.5 g/L glucose, 1.5 g/L sodium bicarbonate, 100 μg/ml
penicillin G/streptomycin, 2.5 μg/ml amphotericin B,
50 μg/ml gentamycin and 10 % foetal bovine serum
(FBS). Cells were cultured at 37 °C, 5 % CO2 and 100 %
humidity.
DAPT (N- [N- (3, 5- difluorophenacetyl)- 1- alanyl]- S-
phenylglycine t- butyl ester (DAPT, LY374973) and EGF
were purchased from Sigma (Sigma-Aldrich Chemie
GmbH, Germany). All experiments were performed ac-
cording to the following conditions: After reaching
80 % confluence, serum starvation followed for 24 h.
Cells were then treated with DAPT at the concentra-
tions of 0.01, 0.1, 1, 10 and 20 μM or/and EGF at the
concentration of 1 μg/ml. In case of DAPT and EGF
co-treatment, EGF was added 30 min prior to DAPT.
The duration of the treatment was determined by the
assay that followed.
Cell proliferation assay
To determine whether DAPT alone or in combination
with EGF, affects the proliferation of cell proliferation,
the 3-[4,5-dimethylthiazol-2-yl]-2,5-dimethyltetrazolium
bromide (MTT) assay was used, as previously described
[24]. Briefly, cells were seeded at a density of 1,5 ×104
cells/well in 24-well plates and cells treated as described
above. Forty-eight hours after agents’ application, MTT
solution (5 mg/ml in PBS) was added at a volume equal
to 1/10, to each well and incubated for 2 h, at 37 °C.
Medium was removed and 100 μl acidified isopropanol
(0.33 ml HCl in 100 ml isopropanol) was added in each
well in order to solubilize the dark blue formazan crystals.
The solution was transferred to 96-well plates and was im-
mediately read in a microplate reader (Tecan, Sunrise,
Magellan 2) at a wavelength of 570 nm using reference
wavelength 620 nm.
Apoptosis assay
All cell lines were plated at 1 × 105 cells per well in 6-well
plates. DAPT was added as previously described. At the
end of a 24 h incubation, cells were washed twice with
PBS, trypsinized for 7 min and centrifuged for 4 min at
166 g. Cells were resuspended in 200 μl 1X binding buffer
(10 mM HEPES pH 7.4, 140 mM NaCl, 2.5 mM CaCl2).
The cell suspension was incubated with 5 μl Annexin
V-FITC in the dark at 25 °C, for 10 min. Then, 10 μl of
the 20 μg/ml propidium iodide stock solution was added,
followed by 200 μl of binding buffer and the cells were
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immediately analysed by flow cytometry [25] (EPICS-XL
of Coulter) according to the manufacturer’s instructions
(rh Annexin V/FITC kit, Bender MedSystems, Germany).
The application of Annexin-V (An) along with propi-
dium iodide (PI) distinguishes 4 populations; the viable
(An−/PI−), the early apoptotic (An+/PI−), the late apoptotic
(An+/PI+) and the necrotic (An−/PI+) cells. The sum of
early and late apoptotic cells calculated as apoptotic cells.
Cell cycle analysis
All cell lines were plated at 1 × 106 cells per Petri dish
and DAPT was added as earlier described. At the end of
the 24 or 48 h incubation, cells were washed twice with
PBS, trypsinized for 7 min and centrifuged for 4 min at
166 g. Cell cycle analysis was performed using the
Muse™ Cell Cycle kit according to the manufacturer’s in-
struction (Merck-Millipore, Germany). Briefly, cells were
washed once with PBS and centrifuged for 5 min at
300 g. The supernatants were discarded leaving approxi-
mately 50 μl of PBS. The pellet of cells was resuspended
in the residual PBS was added drop-wise into a tube
containing 1 ml of ice cold 70 % ethanol while vortexing
at medium speed. The samples were kept at −20 °C for
at least 3 h. Then, 200 μl of fixed cells were centrifuged
at 300 g, for 5 min. The pellet of cells was resuspended
in 200 μl of Muse™ Cell Cycle Reagent and cells were in-
cubated for 30 min, protected from light. After the incu-
bation, cells were analysed by Muse™ Cell Analyzer,
according to the manufacturer’s instructions (Muse™
software, Merck-Millipore, Germany).
Western blot analysis
Cells were plated at Petri dishes. After reaching 80 %
confluence, cells were treated as described above. At the
indicated time point after agents’ application, cells were
collected with scrapper and lysed using lysis buffer
(50 mM Tris–HCl pH 7.5, 150 mM NaCl, 5 mM EDTA,
1 % Triton, 10 % glycerol, 1 mM phenylmethyl-
sulphonyl-fluoride, 2 mM Na-orthovanadate and 10 mM
leupeptin). Protein concentration was determined by Brad-
ford assay. Samples were analysed by immunoblotting as
previously noted [24]. For Beclin-1, an autophagy indicator,
cells were collected 24 h after appropriate treatment and a
goat anti-Beclin-1 (dilution 1:500, Santa Cruz, CA, USA)
was used. For Notch-1 intracelluler domain (NICD), time
course experiments were performed and a sheep anti-
Notch-1 ICD (dilution 1:1000, R&D Systems, Germany)
was used. For EGFR detection, time course experiments
were performed and a rabbit anti-EGFR (dilution 1:6000,
Millipore,Temecula, CA, USA) was used. Actin was used as
internal control for protein quantification and a monoclo-
nal anti-actin antibody (dilution 1:1000, Chemicon, Milli-
pore, Temecula, CA, USA) was used.
Detection of the immunoreactive proteins was performed
by chemiluminescence using horseradish peroxidase sub-
strate SuperSignal (Pierce, Rockford, IIL, USA), according
to the manufacturer’s instructions.
Transmission electron microscopy (TEM)
H661 cells were plated at 1 × 105 cells per well in 6-well
plates. DAPT was added as previously described. At the
end of a 24 h incubation cells were washed with PBS
once, fixed with 2.5 % glutaraldehyde at 4 °C for 2 h and
then washed twice with PBS. Cells were dehydrated in a
graded series of ethanol (50, 70, 80, 90 and 100 %),
transferred in to 100 % acetone for 15 min and embed-
ded in SPURR resin. Ultrathin sections were stained with
uranyl acetate and lead citrate and examined and photo-
graphed with a JEOL 100S transmission electron micro-
scope equipped with an Olympus MegaView G2 digital
camera.
Statistical analysis
Differences between groups and controls were tested by
one-way ANOVA. Each experiment included at least trip-
licate measurements. All results are expressed as mean ±
SEM from at least three independent experiments.
Results
Profile of NSCLC cells according to NICD and EGFR
protein levels
Initially, NSCLC cell lines H23, A549, H661 and HCC827
(Fig. 1a and b) were screened for NICD and EGFR protein
levels. Among four cell lines, H23 expressed the highest,
H661 and HCC827 intermediate and A549 the lowest
NICD protein levels (Fig. 1a). Concerning EGFR, H23
expressed the highest, A549 and HCC827 intermediate
and H661 the lowest, almost undetectable, protein levels
(Fig. 1b). According to ATCC, H23, A549 and H661
cells have wild type (wt) EGFR and HCC827 cells have
mutated (mt) EGFR (https://www.lgcstandards-atcc.org/)
(see Additional file 1: Table S1).
The effect of Notch inhibition in NSCLC cells’ proliferation
Since all cell lines express activated Notch, we studied
the effect of DAPT on the number of unstimulated cells.
The number of H661 cells was significantly decreased in
Fig. 1 Screening of NSCLC cell lines for a) NICD and b) EGFR protein
levels. The images of western blot analysis are representative of three
independent experiments
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a concentration-dependent manner 48 h after DAPT
addition. DAPT had only a minor effect on H23 and
A549 cells, while HCC827 cells were resistant to DAPT
at any tested concentration (Fig. 2a). Based on these data,
the inhibitory effect of DAPT on the number of cells initi-
ated at 10 μM and thus this concentration was used for
the following experiments.
To investigate a possible implication of Notch pathway
with EGFR signalling, we stimulated cells with EGF
1 μg/ml for 30 min prior to addition of DAPT. HCC827
cells were not used in these assays, since they carry ac-
tive mutated EGFR (see Additional file 1: Table S1) and
do not further respond to EGF [26, 27]. EGF alone sig-
nificantly increased only the number of H23 cells, while
it had no effect on A549 and H661 cells. DAPT did not
reverse the stimulatory effect of EGF in H23 cells. On
the other hand, in all cells, the presence of EGF pre-
vented the inhibitory effect of DAPT (Fig. 2a and b).
The effect of DAPT in NICD and EGFR protein levels
In order to correlate the effect of DAPT on cell prolifer-
ation with inhibition of the Notch pathway, we checked
the effect of DAPT on NICD protein levels. DAPT de-
creased NICD protein levels in both H23 and H661 cells,
reaching a maximum effect at 6 h (Fig. 3). Interestingly,
DAPT was more effective in H661 cells, in line with its
effect on the number of cells. We next studied the effect
of EGF alone or in combination with DAPT. EGF alone
did not cause any statistical significant effect on NICD
protein levels either in H23 (Fig. 4a and b) or in H661
(Fig. 4c and d) cells. When EGF was applied 30 min
prior to DAPT, it prevented NICD decrease caused by
DAPT, in both H23 and H661 cells (Fig. 4e, f, g and h),
in line with the corresponding effects on the number of
cells. In case of H23 cells, this prevention was observed
up to 4 h after cells’ treatment, while at 6 h there was an
attenuation effect of EGF to DAPT-induced NICD pro-
tein decrease (Fig. 4e and f). In H661 cells there was a
full prevention at all-time points tested (Fig. 4g and h).
We then tested whether DAPT affected EGFR protein
levels in lung cancer cells. DAPT increased the protein
levels of EGFR in H23 (Fig. 5a) but not H661 cells
(Fig. 5b).
Notch inhibition in NSCLC cells’ death
We estimated whether the reduction in cell number
after DAPT application in lung cancer cells was due to
stimulation of any of the two types of programmed cell
death, apoptosis and autophagy. DAPT did not affect
apoptosis in H23 and HCC827 cells, but increased cell
apoptosis in A549 and H661 cells in a statistically signifi-
cant manner (Fig. 6a and Additional file 2: Figure S1).
Regarding autophagy, we found that DAPT increased
the protein levels of Beclin-1, an indicator of autophagy
[28, 29], only in H661 cells. This increase was 88 % ± 23
and was observed 24 h after DAPTaddition to cells (Fig. 6b
and c). Indeed, autophagosomes were detected in H661
cells 24 h after their treatment with DAPT, using TEM
(Fig. 6d). Although the untreated cells appeared to have
granular cytoplasm, no sign of autophagy was detected
compared to cells after treatment with DAPT.
We then studied the effect of DAPT in cell necrosis
and no significant differences were found in any cell line
tested (data not shown).
Finally, we tested whether DAPT affected cell cycle
distribution 24 h after DAPT application to cells and we
found no effect (data not shown). However, DAPT in-
creased to a small extent the percentage of H23 cells in
G0/G1 phase at 48 h. A slight increase was also found in
A549 cells, without being statistically significant. No
Fig. 2 The effect of DAPT a) alone and b) after stimulation of NSCLC cells with EGF in cell proliferation, 48 h after DAPT application. Each value
represents the means ± SEM from at least three independent experiments. The asterisks denote statistically significant difference between
experimental groups and untreated cells. C *P < 0,05 and ***P < 0,0001
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significant effect was observed in H661 and HCC827
cells (Fig. 6e and Additional file 3: Figure S2).
Discussion
The EGFR pathway plays a vital role in the pathogenesis
and progression of NSCLC. Although the contribution
of EGFR signalling in lung cancer development is well
established, the importance of Notch pathway in lung
cancer is under investigation. The existing data for the
role of Notch in lung cancer are conflicting and not lim-
ited between NSCLC and SCLC groups, but differences
are also demonstrated among NSCLC groups, as well as
among the members of Notch family. Chen et al. re-
ported that Notch 1 was down-regulated in NSCLC cell
lines, while constitutive expression of active Notch 1 in
NSCLC cells caused cell death depending on oxygen
concentration [30]. Another study showed that Notch
3 is active in NSCLC and treatment of cells with a γ-
secretase inhibitor caused a cell proliferation reduction
and increase in apoptosis [17]. Yin et al. suggested that the
controversial effects of Notch signaling are highly context-
dependent [31]. In addition, it has been found that Notch
effect might be dose-dependent in mammary epithelial
MCF-10A cells, whereas high Notch activity caused inhib-
ition of cell proliferation and low Notch activity stimulated
a strong hyperproliferative response [32]. All these con-
flicting data reveal a significant but complicated role of
Notch in cancer development and progression.
In the current study, we selected four NSCLC cell lines
expressing different levels of NICD and EGFR protein
levels. We found that the cell lines exhibited different re-
sponse to the γ-secretase inhibitor DAPT and surprisingly,
Fig. 3 The DAPT effect on NICD protein levels in a) H23 and c) H661 cells in a time dependent manner. The images are representative of three
independent experiments. Western blots were semi-quantified using appropriate software. The results in b) and d) are expressed as % change ± SEM
compared to untreated cells from at least three independent experiments
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Fig. 4 The EGF effect on NICD protein levels, alone in a) H23 and c) H661 cells or prior to DAPT in e) H23 and g) H661 cells in a time dependent
manner. The images are representative of three independent experiments. Western blots were semi-quantified using appropriate software. The
results in b), d), f) and h) are expressed as % change ± SEM compared to untreated cells from at least three independent experiments
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this behavior seems to be related to EGFR status. DAPT
was effective in proliferation of cells expressing wtEGFR,
while it did not affect HCC827 cells expressing mtEGFR.
In addition, differences were observed among the cells
with wtEGFR. We found that although H23 and A549
cells exerted a similar small response to DAPT regarding
cell proliferation, the decrease in cell number was possibly
due to cell cycle arrest for H23 cells and increase in apop-
tosis for A549 cells. In H661 cells that were more sensitive
to DAPT, the decrease in cell number was due to an in-
crease of both apoptosis and autophagy. Our results verify
that the impact of Notch inhibition may vary depending
on cell context, since different types of cell death occurred
in different cell lines. Although in the literature both cell
cycle arrest [33, 34] and apoptosis stimulation [17, 35]
have been described to be induced in cancer cells by
Notch inhibition, there is no previous evidence that Notch
inhibition triggers autophagy in cancer cells. However, it is
known that apoptosis and autophagy are two mechanisms
of programmed cell death that may co-exist and act syner-
gistically [36]. A link between Notch pathway and autoph-
agy was presented in a recent paper where the authors
observed that loss of autophagy leads to precocious Notch
activation during Drosophila oogenesis [37]. We might as-
sume that H661 cells were more sensitive to DAPT be-
cause of the dual induction of apoptosis and autophagy
compared with H23 and A549 cells, where only one type
of cell death was activated. The sensitivity of H661 cells to
DAPT might be correlated with the EGFR protein levels,
since H661 cells expressed the lowest EGFR levels com-
pared with H23 and A549 cells. The low EGFR protein
levels may render H661 cells more sensitive to EGFR-
independent signaling pathways regarding cell proliferation.
This hypothesis could be supported by the failure of EGF
Fig. 5 The effect of DAPT in EGFR protein levels in several time points in a) H23 and c) H661 cells. The images are representative of three
independent experiments. Western blots were semi-quantified using appropriate software. The results in b) and d) are expressed as %
change ± SEM compared to untreated cells from at least three independent experiments
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Fig. 6 (See legend on next page.)
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alone to stimulate H661 cell proliferation. Although, EGF
failed to stimulate A549 cell proliferation too, this may
be explained by the existence of Kras mutation in these
cells [38].
Since our data indicated that the effect of γ-secretase
inhibitors might be affected by the EGFR status, the three
cell lines expressing wtEGFR were stimulated with EGF
prior to DAPT addition. The stimulation of all cells with
EGF fully prevented the inhibition of cell proliferation by
DAPT. This is in agreement with the lack of effect of
DAPT in HCC827 cells bearing active mtEGFR [26, 27].
Although our data are not conclusive, this is the first indi-
cation in the literature that EGFR activation may affect
Notch signalling in NSCLC cells. A similar effect regard-
ing NICD protein levels was observed when cells were
treated with EGF prior to DAPT application. EGF attenu-
ated the reduction of NICD levels caused by DAPT.
Nevertheless, since there is no direct evidence for the
impact of EGF to NICD protein, we might assume that
ERK1/2 phosphorylation induced by EGF activates Notch
pathway [39]. Regarding a bidirectional effect between
Notch and EGFR pathway, to our knowledge, there is
evidence from breast cancer cells where Notch over-
expression caused EGFR up-regulation [19]. A similar
effect has been described in gliomas through p53 regulation
[40]. Αn opposite effect has been described in breast cancer
cells where HER-2 inhibition using transtuzumab caused
increased Notch 1 activity [41]. In this study, inhibition of
Notch activation by DAPT increased EGFR protein levels
in H23 cells without affecting the EGFR levels in H661
cells. We might speculate that this increase offered a
relative resistance in H23 cells compared to H661 cells
in cell proliferation after DAPT treatment.
This study presents indications that EGFR and Notch
signalling pathways crosstalk in human lung cancer cell
lines. In more recent research, it has been shown that in
hypoxia, ADAM12 could be the linker between the two
pathways since it mediates the release of heparin-binding
EGF-like growth factor after Notch activation that leads to
EGFR activation and cell invasion promotion. These experi-
ments performed in head and neck, lung and pancreatic
cancer cells [42].
Conclusions
In conclusion, the interaction of Notch with EGFR re-
vealed from our data might imply that a dual inhibition
of these pathways might be promising in NSCLC cells
that express high EGFR protein levels. This indicates an
attractive new avenue of combination approaches for
cancer therapy that may enhance the potency of EGFR
inhibitory agents on tumours.
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